Back to search results

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Abroad (travel likely)Active Not RecruitingPHASE1

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UCLA Jonsson Comp Cancer Center, Los Angeles, California, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Saint-Herblain, France

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Gliwice, Poland

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)

No study contact email or phone is listed for this trial.